Eli Lilly | 2017

Share this content:

U.S. Revenue: $17 billion (up 22.3%)

Global Revenue: $21 billion (up 6%)

Top Brands: Humalog ($1.6B); Cialis ($1.4B); Alimta ($1.1B); Humulin ($861m), Forteo ($770m)

R&D Spend: $5.2B (up 9.3%); 24% of revenue

Planned Launches: Lasmiditan (migraine); AZD3293 (Alzheimer's disease)

Upcoming Patent Expirations: Strattera, Effient, Cialis

Eli Lilly has faced a rough patch. Last November, the company took a $150 million charge over its failed high-profile Alzheimer's disease drug solanezumab. Then, in April, the FDA unexpectedly ­rejected its potential blockbuster rheumatoid arthritis drug baricitinib. The agency asked for more safety data, a move that could punt its ap­proval to 2020. Its diabetes franchise also came under scrutiny, with the company disclosing in an SEC filing that two state attorneys general are investigating the drugmaker over insulin pricing. And to top it off, one of its highest-profile diabetes products, Jardiance, is off to a slow start, especially in light of blockbusteresque expectations from the analyst community. It only generated $74 million in sales during the first three months of 2017 — even after the FDA said in December that the drug reduced the risk of cardiovascular death. Lilly's newer products, however, have been offered hope: Diabetes treatment Trulicity and lung-cancer drug Cyramza saw combined sales of more than $800 million in the first three months of the year. Plus the Indianapolis-based drugmaker recently received some good news from its oncology division: Its experimental breast-cancer drug abemaciclib hit its primary endpoint in a Phase III trial.

Share this content:
Scroll down to see the next article